news
01-29-2013, 03:30 AM
The industry’s lobbying effort could blunt new competition to its products and reduce the savings anticipated in the federal health care overhaul.http://rss.nytimes.com/c/34625/f/642562/s/27ff2685/mf.gif
More... (http://www.nytimes.com/2013/01/29/business/battle-in-states-on-generic-copies-of-biotech-drugs.html?partner=rss&emc=rss)
More... (http://www.nytimes.com/2013/01/29/business/battle-in-states-on-generic-copies-of-biotech-drugs.html?partner=rss&emc=rss)